Pharmaceutical company Novo Nordisk A/S (ADR) (NYSE:NVO) is one of those companies which prove that being less diversified can be good too.

Novo Nordisk A/S (ADR) (NYSE:NVO) wants to expand the earnings potential of its bestselling diabetes drug Victoza. The drug already has FDA permission to note the potential for weight loss on Victoza's label.

Novo Nordisk A/S (NVO, NOVO-B.KO), the world's top maker of insulin, said its hotly anticipated Tresiba drug may not hit the U.S.

Zacks' analyst wrote, �Novo Nordisk posted first quarter 2013 earnings of $1.94 per ADR, up 32.5% from the year-ago period.

Novo Nordisk logo Zacks reaffirmed their neutral rating on shares of Novo Nordisk (NYSE: NVO) in a report issued on Monday, Stock Ratings Network reports.